SE522723C2 - Användning av kollagenas vid behandling av Dupuytrens sjukdom - Google Patents
Användning av kollagenas vid behandling av Dupuytrens sjukdomInfo
- Publication number
- SE522723C2 SE522723C2 SE9800806A SE9800806A SE522723C2 SE 522723 C2 SE522723 C2 SE 522723C2 SE 9800806 A SE9800806 A SE 9800806A SE 9800806 A SE9800806 A SE 9800806A SE 522723 C2 SE522723 C2 SE 522723C2
- Authority
- SE
- Sweden
- Prior art keywords
- collagenase
- approx
- medicament according
- disease
- abc units
- Prior art date
Links
- 108060005980 Collagenase Proteins 0.000 title claims abstract description 39
- 102000029816 Collagenase Human genes 0.000 title claims abstract description 39
- 229960002424 collagenase Drugs 0.000 title claims abstract description 39
- 208000001708 Dupuytren contracture Diseases 0.000 title claims abstract description 10
- 238000011282 treatment Methods 0.000 title claims description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 10
- 206010011732 Cyst Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 206010062575 Muscle contracture Diseases 0.000 abstract description 3
- 208000006111 contracture Diseases 0.000 abstract description 3
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 210000003811 finger Anatomy 0.000 description 13
- 239000003085 diluting agent Substances 0.000 description 6
- 210000000651 myofibroblast Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002435 tendon Anatomy 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000005452 bending Methods 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000193159 Hathewaya histolytica Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000004933 right little finger Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010013295 Microbial collagenase Proteins 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000002683 hand surgery Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 208000030346 palmar fibromatosis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/826,015 US6086872A (en) | 1997-03-27 | 1997-03-27 | Amelioration of dupuytren's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9800806D0 SE9800806D0 (sv) | 1998-03-12 |
| SE9800806L SE9800806L (sv) | 1998-09-28 |
| SE522723C2 true SE522723C2 (sv) | 2004-03-02 |
Family
ID=25245473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9800806A SE522723C2 (sv) | 1997-03-27 | 1998-03-12 | Användning av kollagenas vid behandling av Dupuytrens sjukdom |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6086872A (enExample) |
| AU (1) | AU733208B2 (enExample) |
| DE (1) | DE19813748A1 (enExample) |
| DK (1) | DK177324B1 (enExample) |
| FR (2) | FR2772273B1 (enExample) |
| GB (1) | GB2323530B (enExample) |
| NO (1) | NO981388L (enExample) |
| SE (1) | SE522723C2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| US6022539A (en) * | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
| GB0306165D0 (en) * | 2003-03-18 | 2003-04-23 | Delta G Ltd | Medical treatment |
| PL1846022T3 (pl) * | 2005-01-21 | 2016-06-30 | Univ New York State Res Found | Sposoby leczenia zarostowego zapalenia torebki stawowej |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| ITPD20050207A1 (it) | 2005-07-07 | 2007-01-08 | Fidia Farmaceutici | Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| WO2008100833A2 (en) * | 2007-02-13 | 2008-08-21 | Auxilium International Holdings, Inc. | Production of recombinant collagenases colg and colh in escherichia coli |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| JP5649589B2 (ja) * | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用 |
| WO2010111525A2 (en) | 2009-03-25 | 2010-09-30 | Agee, John, M., Trustee Of The John M. Agee Trust Of August 15, 1996 | Treatment of carpal tunnel syndrome by injection of the flexor retinaculum |
| EP2632446B1 (en) * | 2010-10-30 | 2018-12-12 | Oxford University Innovation Limited | Treatment for dupuytren's disease |
| WO2012125948A1 (en) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| KR101921363B1 (ko) | 2011-07-20 | 2018-11-22 | 메디운드 리미티드 | 결합 조직 질환을 치료하기 위한 브로멜라인으로부터의 단백분해 추출물 |
| GB201119089D0 (en) | 2011-11-04 | 2011-12-21 | Isis Innovation | Treatment of musculoskeletal fibroproliferative disorders |
| EP4276180A3 (en) | 2012-01-12 | 2024-01-10 | Endo Global Ventures | Clostridium histolyticum enzyme |
| US20150079069A1 (en) * | 2012-04-30 | 2015-03-19 | Elastomics Ab | Methods for modification of tissues |
| WO2014066622A2 (en) | 2012-10-24 | 2014-05-01 | The Research Foundation For The State University Of New York | Use of collagenase to treat glaucoma |
| US20150196625A9 (en) | 2013-01-07 | 2015-07-16 | Rudolph D. Paladini | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof |
| AU2014228477B2 (en) | 2013-03-15 | 2019-05-23 | Biospecifics Technologies Corporation | Treatment method and product for uterine fibroids using purified collagenase |
| CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| KR20250021648A (ko) | 2017-03-01 | 2025-02-13 | 엔도 오퍼레이션즈 리미티드 | 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법 |
| WO2018183582A2 (en) | 2017-03-28 | 2018-10-04 | Endo Ventures Limited | Improved method of producing collagenase |
| US11872267B2 (en) | 2019-10-15 | 2024-01-16 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338300A (en) * | 1981-02-05 | 1982-07-06 | The Regents Of The University Of California | Use of purified clostridial collangenase in the treatment of Peyronie's disease |
| US5173295A (en) * | 1990-10-05 | 1992-12-22 | Advance Biofactures Of Curacao, N.V. | Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor |
| US5393792A (en) * | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
-
1997
- 1997-03-27 US US08/826,015 patent/US6086872A/en not_active Ceased
-
1998
- 1998-03-11 GB GB9805050A patent/GB2323530B/en not_active Expired - Lifetime
- 1998-03-12 SE SE9800806A patent/SE522723C2/sv not_active IP Right Cessation
- 1998-03-18 FR FR9803320A patent/FR2772273B1/fr not_active Expired - Lifetime
- 1998-03-23 DK DKPA199800403A patent/DK177324B1/da not_active IP Right Cessation
- 1998-03-26 AU AU59661/98A patent/AU733208B2/en not_active Expired
- 1998-03-26 NO NO981388A patent/NO981388L/no not_active Application Discontinuation
- 1998-03-27 DE DE19813748A patent/DE19813748A1/de not_active Expired - Lifetime
-
2005
- 2005-03-30 US US11/094,753 patent/USRE39941E1/en not_active Expired - Lifetime
-
2011
- 2011-08-18 FR FR11C0033C patent/FR11C0033I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK40398A (da) | 1998-09-28 |
| FR11C0033I2 (fr) | 2012-03-16 |
| DK177324B1 (da) | 2013-01-07 |
| AU733208B2 (en) | 2001-05-10 |
| DE19813748A1 (de) | 1998-10-01 |
| FR2772273A1 (fr) | 1999-06-18 |
| USRE39941E1 (en) | 2007-12-18 |
| GB2323530B (en) | 2001-10-10 |
| GB2323530A (en) | 1998-09-30 |
| SE9800806D0 (sv) | 1998-03-12 |
| AU5966198A (en) | 1998-10-01 |
| NO981388L (no) | 1998-09-28 |
| GB9805050D0 (en) | 1998-05-06 |
| US6086872A (en) | 2000-07-11 |
| NO981388D0 (no) | 1998-03-26 |
| SE9800806L (sv) | 1998-09-28 |
| FR2772273B1 (fr) | 2003-04-25 |
| FR11C0033I1 (enExample) | 2011-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE522723C2 (sv) | Användning av kollagenas vid behandling av Dupuytrens sjukdom | |
| US5552162A (en) | Method for improvement of scar size and appearance | |
| US4524065A (en) | Method for the prevention and treatment of scars with enzymes | |
| Liu et al. | Biological amnion prevents flexor tendon adhesion in zone II: a controlled, multicentre clinical trial | |
| Bates et al. | Mannose-6-phosphate, an inhibitor of transforming growth factor-β, improves range of motion after flexor tendon repair | |
| JP2011507862A (ja) | 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用 | |
| US5589171A (en) | Treatment of Dupuytren's disease with collagenase | |
| WO1994017839A9 (en) | Method for the improvement of scar size and appearance | |
| JP2016135799A (ja) | 損傷した創傷治癒組成物および治療 | |
| JP2011506446A (ja) | 損傷した創傷治癒組成物および治療 | |
| Meyers et al. | Effect of hyaluronic acid/chondroitin sulfate on healing of full‐thickness tendon lacerations in rabbits | |
| JP2017025076A (ja) | 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用 | |
| Kelly | Keratins in wound healing | |
| JP2011507858A (ja) | 整形外科状態の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた、抗コネキシンペプチドの使用 | |
| NO333945B1 (no) | Anvendelse av kollagenase til fremstilling av et legemiddel for behandling av et individ som lider av Peyronies sykdom. | |
| Oryan et al. | Response of a collagenase-induced tendon injury to treatment with a polysulphated glycosaminoglycan (Adequan) | |
| JP2014208699A (ja) | 外科的癒着の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた抗コネキシンペプチドの使用 | |
| JP2015013880A (ja) | 外科的癒着の治療のための抗コネキシンポリヌクレオチドの使用 | |
| JPH04211019A (ja) | 創傷治癒促進のためのトロンボスポンデインの使用 | |
| CN109069661A (zh) | 利用聚合蛋白共轭物的治疗 | |
| Cutcutache et al. | 61802 Bimekizumab reduces systemic inflammation and cardiovascular risk gene signatures in psoriatic disease | |
| CN114774389A (zh) | 基于光控型CRISPR/Cas13d基因编辑系统的基因编辑方法、组合物及应用 | |
| JP4832515B2 (ja) | 創傷治癒用の組成物及びその使用 | |
| Caporossi et al. | Epidermal growth factor in topical treatment following epikeratoplasty | |
| Byrne | Hand surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Application for supplementary protection certificate filed |
Free format text: PRODUCT NAME: KOLLAGENAS CLOSTRIDIUM HISTOLYTICUM; REG. NO/DATE: EU/1/11/671/001 20110228 Spc suppl protection certif: 1190022-2.L |
|
| SPCG | Supplementary protection certificate granted |
Free format text: PRODUCT NAME: KOLLAGENAS CLOSTRIDIUM HISTOLYTICUM; REG. NO/DATE: EU/1/11/671/001 20110228 Spc suppl protection certif: 1190022-2 Expiry date: 20180313 Extension date: 20230312 |
|
| NUG | Patent has lapsed |